ArticleBlood advances2017
Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease.
Article in Blood advances, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04606069 (Clinical Trial on the Safety and Efficacy of Regadenoson for Moderate to Severe COVID-19 Adult Patients), which is not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Trial on the Safety and Efficacy of Regadenoson for Moderate to Severe COVID-19 Adult Patients
Who cites it
28 citing papers in PubMed, 45 citations in OpenAlex.
- Trial
- Contrast-enhanced ultrasound detects changes in microvascular blood flow in adults with sickle cell disease.PloS one · 2019Trial
- Regadenoson in the rehabilitation of marginal donor lungs on ex vivo lung perfusion: A blinded multicenter randomized controlled clinical trial.JTCVS open · 2025Article
- Emergency care for children with sickle cell disease: a focus on pain and fever.Expert review of hematology · 2025Review
- Article
- Using disease-modifying therapies in sickle cell disease.Hematology. American Society of Hematology. Education Program · 2023Article
- Regadenoson for the treatment of COVID-19: A five case clinical series and mouse studies.PloS one · 2023Article
- AInternational review of neurobiology · 2023Article
- The developmental journey of therapies targeting purine receptors: from basic science to clinical trials.Purinergic signalling · 2022Review
- Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: Report from a U.S. regional collaborative.Frontiers in genetics · 2022Article
- Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary events.Journal of translational medicine · 2021Review
- Research in Sickle Cell Disease: From Bedside to Bench to Bedside.HemaSphere · 2021Review
- Review
- A Comprehensive Review of the Treatment and Management of Pain in Sickle Cell Disease.Current pain and headache reports · 2020Review
- Innate immune cells, major protagonists of sickle cell disease pathophysiology.Haematologica · 2020Review
- Drug Therapies for the Management of Sickle Cell Disease.F1000Research · 2020Review
- Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease.Therapeutic advances in hematology · 2020Review
- The Evolving Pharmacotherapeutic Landscape for the Treatment of Sickle Cell Disease.Mediterranean journal of hematology and infectious diseases · 2020Review
- Adenosine Receptor Agonists Exhibit Anti-Platelet Effects and the Potential to Overcome Resistance to P2YMolecules (Basel, Switzerland) · 2019Article
- Emerging disease-modifying therapies for sickle cell disease.Haematologica · 2019Review
Corrections and comments
- Erratum issued
Authors and funding
15 authors at 9 institutions in 1 country.
Funding
Abstract
Adenosine A
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.